glucagon has been researched along with rosiglitazone in 5 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 4,749 | 556 | 1,818 |
| Protein | Taxonomy | glucagon (IC50) | rosiglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
| Bile salt export pump | Homo sapiens (human) | 4.5853 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buckingham, RE; Lister, CA; Smith, SA; Toseland, CD | 1 |
| Dharmalingam, M; Kumar, P | 1 |
| Roden, M; Stingl, H | 1 |
| Choi, MS; Jeon, SM; Jeong, YJ; Kim, DJ; Kim, HJ; Kwon, JH; Lee, MK; Moon, KD; Park, YB | 1 |
| Chodavarapu, H; Elased, KM; Grobe, N; Madhu, M; Salem, ES; Somineni, HK | 1 |
2 review(s) available for glucagon and rosiglitazone
| Article | Year |
|---|---|
New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).
Topics: Amyloid; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Peptide Fragments; Protein Precursors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
[Future targets in the treatment of type 2 diabetes].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Forecasting; Glucagon; Glucagon-Like Peptide 1; Glucose; Glycated Hemoglobin; Glycogen Synthase Kinase 3; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Peroxidation; Metabolic Syndrome; Mice; Oxazines; Peptide Fragments; Phenylpropionates; Protein Precursors; Rats; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors | 2004 |
3 other study(ies) available for glucagon and rosiglitazone
| Article | Year |
|---|---|
Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
Topics: Aging; Animals; Cataract; Diabetes Mellitus, Type 2; Glucagon; Hyperglycemia; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Pancreas; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Thirst; Time Factors | 2000 |
Beneficial effect of chungkukjang on regulating blood glucose and pancreatic beta-cell functions in C75BL/KsJ-db/db mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fermentation; Glucagon; Glucokinase; Glycated Hemoglobin; Glycine max; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Isoflavones; Leptin; Liver; Male; Mice; Mice, Inbred C57BL; Pancreas; Rosiglitazone; Soybean Proteins; Thiazolidinediones | 2008 |
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion.
Topics: ADAM Proteins; ADAM17 Protein; Albuminuria; Angiotensin-Converting Enzyme 2; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucose Tolerance Test; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Kidney Diseases; Male; Membrane Proteins; Mice; Peptidyl-Dipeptidase A; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-3; Triglycerides | 2013 |